Status: Recruiting
The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study is the Largest U.S.-Based Prospective Study Demonstrating a Circulating Fetal Cell (CFC) Based Approach to Non-invasive Fetal Risk Assessment
The goal of the ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) study is to compare the concordance of results of a novel non-invasive circulating fetal cell (CFC) assay to the results of prenatal invasive diagnostic testing or postnatal genetic and clinical diagnosis of the resulting neonate. This is a prospective study of pregnant individuals.
Participants needed: 1,000
Trial details
Biological sex: FemaleType: ObservationalSponsor: BillionToOne Inc.Updated: Jun 12, 2026Locations: 6
Eligibility criteria
pregnant individuals between 10 and 20 weeks of gestation [+1]